2seventy bio, Inc.
TSVT
$4.95
$2.1576.79%
| Weiss Ratings | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.34 | |||
| Price History | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 87.50% | |||
| 30-Day Total Return | 95.65% | |||
| 60-Day Total Return | 25.32% | |||
| 90-Day Total Return | -0.60% | |||
| Year to Date Total Return | 67.23% | |||
| 1-Year Total Return | 8.08% | |||
| 2-Year Total Return | -52.17% | |||
| 3-Year Total Return | -58.58% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -53.26% | |||
| 52-Week Low % Change | 22.27% | |||
| Price | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.99 | |||
| 52-Week Low Price | $2.29 | |||
| 52-Week Low Price (Date) | Feb 07, 2025 | |||
| 52-Week High Price (Date) | Apr 01, 2024 | |||
| Valuation | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 144.45M | |||
| Enterprise Value | 199.49M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.86 | |||
| Earnings Per Share Growth | -52.49% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.21 | |||
| Price/Book (Q) | 0.63 | |||
| Enterprise Value/Revenue (TTM) | 4.37 | |||
| Price | $4.95 | |||
| Enterprise Value/EBITDA (TTM) | -1.49 | |||
| Enterprise Value/EBIT | -1.40 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 52.26M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 675 7270 | |||
| Address | 60 Binney Street Cambridge, MA 02142 | |||
| Website | www.2seventybio.com | |||
| Country | United States | |||
| Year Founded | 2021 | |||
| Profitability | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -311.98% | |||
| Profit Margin | -207.25% | |||
| Management Effectiveness | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.54% | |||
| Return on Equity | -- | |||
| Income Statement | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 45.62M | |||
| Total Revenue (TTM) | 45.62M | |||
| Revenue Per Share | $0.87 | |||
| Gross Profit (TTM) | -90.73M | |||
| EBITDA (TTM) | -133.86M | |||
| EBIT (TTM) | -142.33M | |||
| Net Income (TTM) | -94.55M | |||
| Net Income Avl. to Common (TTM) | -94.55M | |||
| Total Revenue Growth (Q YOY) | 12.46% | |||
| Earnings Growth (Q YOY) | 86.13% | |||
| EPS Diluted (TTM) | -1.86 | |||
| EPS Diluted Growth (Q YOY) | 86.42% | |||
| Balance Sheet | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 192.40M | |||
| Cash Per Share (Q) | $3.68 | |||
| Total Current Assets (Q) | 218.48M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 228.10M | |||
| Current Ratio (Q) | 4.955 | |||
| Book Value Per Share (Q) | $4.43 | |||
| Total Assets (Q) | 503.85M | |||
| Total Current Liabilities (Q) | 44.10M | |||
| Total Debt (Q) | 247.45M | |||
| Total Liabilities (Q) | 275.74M | |||
| Total Common Equity (Q) | 228.10M | |||
| Cash Flow | TSVT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 106.66M | |||
| Cash from Financing (TTM) | 667.00K | |||
| Net Change in Cash (TTM) | -31.79M | |||
| Levered Free Cash Flow (TTM) | -94.49M | |||
| Cash from Operations (TTM) | -139.12M | |||
